Genfit 将来の成長

Future 基準チェック /56

Genfit利益と収益がそれぞれ年間41.2%と20.1%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に5.5% 2.1%なると予測されています。

主要情報

41.2%

収益成長率

2.1%

EPS成長率

Biotechs 収益成長	42.7%
収益成長率	20.1%
将来の株主資本利益率	5.5%
アナリストカバレッジ	Low
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:XUP - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	75	12	7	8	4
12/31/2025	50	-18	12	12	4
12/31/2024	98	34	5	6	3
6/30/2024	80	22	-43	-42	N/A
3/31/2024	57	-3	-50	-48	N/A
12/31/2023	34	-29	-58	-55	N/A
9/30/2023	32	-32	-55	-53	N/A
6/30/2023	29	-34	-52	-50	N/A
3/31/2023	28	-29	-62	-61	N/A
12/31/2022	26	-24	-73	-73	N/A
9/30/2022	60	12	4	4	N/A
6/30/2022	94	48	80	80	N/A
3/31/2022	90	58	90	90	N/A
12/31/2021	85	67	99	100	N/A
9/30/2021	46	14	10	11	N/A
6/30/2021	6	-39	-79	-79	N/A
3/31/2021	7	-70	-88	-88	N/A
12/31/2020	9	-101	-97	-96	N/A
9/30/2020	24	-84	-73	-71	N/A
6/30/2020	39	-67	-49	-46	N/A
3/31/2020	39	-66	-49	-47	N/A
12/31/2019	39	-65	-50	-48	N/A
9/30/2019	23	-80	-62	-60	N/A
6/30/2019	8	-94	-73	-71	N/A
3/31/2019	8	-87	-66	-64	N/A
12/31/2018	7	-80	-59	-56	N/A
9/30/2018	7	-75	N/A	N/A	N/A
6/30/2018	7	-70	-58	-56	N/A
3/31/2018	7	-63	N/A	-53	N/A
12/31/2017	7	-56	N/A	-50	N/A
9/30/2017	7	-50	N/A	N/A	N/A
6/30/2017	8	-44	N/A	-40	N/A
3/31/2017	7	-39	N/A	-34	N/A
12/31/2016	7	-34	N/A	-27	N/A
9/30/2016	6	-27	N/A	-23	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-19	N/A	-16	N/A
12/31/2015	4	-17	N/A	-15	N/A
9/30/2015	5	-17	N/A	-17	N/A
6/30/2015	5	-17	N/A	-19	N/A
3/31/2015	6	-17	N/A	-17	N/A
12/31/2014	7	-17	N/A	-15	N/A
9/30/2014	7	-15	N/A	-15	N/A
6/30/2014	7	-14	N/A	-14	N/A
3/31/2014	6	-13	N/A	-11	N/A
12/31/2013	6	-13	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: XUPの予測収益成長率 (年間41.2% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: XUPの収益 ( 41.2% ) はGerman市場 ( 20.9% ) よりも速いペースで成長すると予測されています。

高成長収益: XUPの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: XUPの収益 ( 20.1% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: XUPの収益 ( 20.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: XUPの自己資本利益率は、3年後には低くなると予測されています ( 5.5 %)。

Genfit 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2022

Recent updates

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 20%

First half 2024 earnings released: EPS: €0.61 (vs €0.42 loss in 1H 2023)

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Full year 2023 earnings released: €0.58 loss per share (vs €0.48 loss in FY 2022)

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

New minor risk - Profitability

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

New minor risk - Share price stability

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings released: €0.48 loss per share (vs €1.50 profit in FY 2021)

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: €1.51 (vs €2.61 loss in FY 2020)

Forecast to breakeven in 2022

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.60 loss per share (vs €1.76 loss in FY 2019)

Full year 2020 earnings released

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: €5.19

Genfit SA, Annual General Meeting, May 28, 2021

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.75

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.59

New 90-day low - €3.99

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘